Protara Therapeutics Shareholders Approve Doubling Authorized Common Stock to 200M

Protara Therapeutics announced the results of its 2026 Annual Meeting of Stockholders, where shareholders approved several key proposals, most notably an amendment to double the company's authorized shares of common stock.

Key Details

• Authorized Share Increase: Stockholders approved an amendment to the company's Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000.
• Director Elections: Three Class III directors, Jesse Shefferman, Barry Flannelly, and Cynthia Smith, were elected to the Board of Directors to serve until the 2029 annual meeting.
• Other Approvals: Shareholders also ratified the selection of Ernst and Young LLP as the independent public accounting firm and approved an amendment to the 2024 Equity Incentive Plan. The meeting was held on June 12, 2026.